The Inhibitory Effect of Heparin and Related Glycosaminoglycans on Neutrophil Chemotaxis

Summary

Clinical observations have shown that heparin has antiinflammatory activities. The effect of heparin on neutrophil chemotaxis was evaluated in vitro in the Boyden Chamber. This method enabled differentiation between the direct effects of heparin on neutrophil migration and locomotion, and its effects on chemotactic factors. Heparin inhibited both the random migration and directed locomotion of human neutrophils toward zymosan-activated serum (ZAS) and F-met-leu-phe (FMLP). Inhibition was found to be dependent on the concentrations of the heparin and of the chemotactic factors. No specific binding of heparin to the neutrophils could be demonstrated, and heparin’s inhibitory effects were eliminated by simple washing of the cells. When added directly to the chamber containing chemotactic factor, heparin inhibited the chemotactic activity of ZAS but not that of FMLP, suggesting a direct inhibitory effect against C5a, the principal chemotactic factor in ZAS.

Experiments performed with low-molecular-weight heparin, N-desulfated heparin, dextran sulfate, chondroitin sulfate and dextran indicated that the inhibitory effects of heparin on neutrophil chemotaxis are not related to its anticoagulant activity, but probably depend on the degree of sulfation of the heparin molecule.

Keywords

Heparin - Neutrophil - Chemotaxis

• References

• 1 Miller ME. Pathology of chemotaxis and random motility. Semin Hematol 1975; 12: 59-82
• 2 Senn HJ, Jungi WF. Neutrophil migration in health and disease. Semin Hematol 1975; 12: 27-45
• 3 Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: The case for glucose control. Am J Med 1982; 72: 439-450
• 4 Ehrenfeld M, Levy M, Bar Eli M, Gallily R, Eliakim M. Effect of colchicine on polymorphonuclear leucocyte chemotaxis in human volunteers. Br J Clin Pharmacol 1980; 10: 297-300
• 5 Rivkin I, Foschi GV, Rosen CH. Inhibition of in vitro neutrophil chemotaxis and spontaneous motility by anti-inflammatory agents. Proc Soc Exp Biol Med 1976; 153: 236-240
• 6 Spisani S, Vanzini G, Traniello S. Inhibition of human leucocyte locomotion by anti-inflammatory drugs. Experientia 1979; 35: 803-804
• 7 Katler E, Weissmann G. Steroids, aspirin and inflammation. Inflammation 1977; 2: 295-307
• 8 Jaques LB. Heparins - Anionic polyelectrolyte drugs. Pharmacol Rev 1981; 31: 99-166
• 9 Waldman AA, Marx G, Goldstein J. Heparin as inhibitor of mammalian protein synthesis. Biochim Biophys Acta 1974; 343: 321-329
• 10 Rosenberg RD, Damus PS. The purification and mechanism of action of human anti-thrombin - heparin cofactor. J Biol Chem 1973; 248: 6490-6505
• 11 Crowley CA, Cumutte JT, Rosin RE, Andre-Schwartz J, Gallin JI, Klempner M, Snyderman R, Southwick FS, Stossel TP, Babior BM. An inherited abnormality of neutrophil ashesion. N Engl J Med 1980; 302: 1163-1168
• 12 Jordan R, Beeler D, Rosenberg R. Fractionation of low molecular weight heparin species and their interaction with anti-thrombin. J Biol Chem 1979; 254: 2902-2913
• 13 Zigmond SH, Hirsch JG. Leukocyte locomotion and chemotaxis: New methods for evaluation and demonstration of cells-derived chemotactic factor. J Exp Med 1973; 137: 387-410
• 14 Matzner Y, Partridge RE H, Babior BM. A chemotactic inhibitor in synovial fluid. Immunology 1983; 49: 131-138
• 15 Shanberge JN, Kambayashi J, Nakagawa M. The interaction of platelets with a tritium-labelled heparin. Thromb Res 1976; 9: 595-598
• 16 Glimelius B, Busch C, Höök M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res 1978; 12: 773-782
• 17 Kjellen L, Oldberg A, Rubin K, Höök M. Binding of heparin and heparan sulfate to rat liver cells. Biochem Biophys Res Commun 1977; 74: 126-128
• 18 Mathews MB, Cifonelli JA. Technical information: Acid mucopolysaccharide reference standards NIH Contract (No. N01-AM-5-2205).
• 19 Chenoweth D, Hugli TE. Demonstration fo specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978; 75: 3943-3947
• 20 Fernandez HN, Hugli TE. Chemical description of the carbohydrate and polypeptide portions of human C5a. J Immunol 1976; 117: 1688-1694
• 21 Strunk R, Colten HR. Inhibition of the enzymatic activity of the first component of complement (C1) by heparin. Clin Immunol Immunopathol 1976; 6: 248-255
• 22 Reapple E, Hill HU, Loos M. Mode of interaction of different poly anions with the first (C1, C1), the second (C2) and thejourth (C4) component of complement - I: Effect on fluid phase Cl and on Cl bound to EA or to EAC4. Immunochemistry 1976; 13: 251-255
• 23 Loos M, Volanakis JE, Stroud RM. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement - II: Effect of poly anions on the binding of C2 to EAC4b. Immunochemistry 1976; 13: 257-261
• 24 Loos M, Volanakis JE, Stroud RM. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement - III: Inhibition of C4 and C2 binding sites on Cls by polyanions. Immunochemistry 1976; 13: 789-791
• 25 Fiedel BA, Gewurz H. Complement (C1q), poly anions and platelet activation. Thromb Res 1980; 19: 729-731
• 26 Takada A, Takada Y. Interaction of C1s and C1 inactivator in the presence of heparin, dextran sulfate and protamine sulfate. Thromb Res 1980; 18: 847-859
• 27 Rent R, Myhrman R, Fiedel BA, Gewurz H. Potentiation of C1- esterase inhibitor activity by heparin. Clin Exp Immunol 1976; 23: 264-271
• 28 Caughman GB, Boackle RJ, Vesely J. A postulated mechanism for heparin’s potentiation of Cl inhibitor function. Mol Immunol 1982; 19: 287-295
• 29 Avila J, Convit J. Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J 1975; 152: 57-64
• 30 West BC, Dunphy CH, Moore CA. Human neutrophil N-acetyl-β-D-glucosaminidase: Heparin inhibition. Biochem Med 1983; 29: 1-13
• 31 West BC, Rosenthal AS, Gelb NA, Kimball HR. Separation and characterization of human neutrophil granules. Am J Pathol 1974; 77: 41-66
• 32 West BC, Gelb NA, Rosenthal AS. Isolation and partial characterization of human eosinophil granules. Comparison to neutrophils. Am J Pathol 1975; 81: 575-588
• 33 Wolff SM, Dale DC, Clark RA, Root RK, Kimball HR. The Chediak-Higashi syndrome: Studies of host defence. Ann Intern Med 1972; 76: 293-306
• 34 Kimball HR, Ford GH, Wolff SM. Lysosomal enzymes in normal and Chediak-Higashi blood leukocytes. J Lab Clin Med 1975; 86: 616-630
• 35 Ginzburg I, Lahav M. The effect of leukocyte hydrolases on bacteria. XVI: The activation of leukocyte factors and cationic substances of autolytic enzymes in Staphylococcus aureus: Modulation of anionic polyelectrolytes in relation to survival of bacteria in inflammatory exudates. Inflammation 1982; 6: 269-284
• 36 Allgower M. Über die Wirkung von Heparin polyanetholsulfosaurem Natrium (Liquoid Roche) und tribasischem Natriumcitrat auf menschliche Leukozyten in vitro. Schweiz Med Wochenschr 1947; 77: 40-43
• 37 Ginzburg I, Quie PG. Modulation of human polymorphonuclear leukocyte chemotaxis by leukocyte extracts, bacterial products, inflammatory exudates and polyelectrolytes. Inflammation 1980; 4: 301-311